Skip to content

A single patient trial with Ataluren in one case of severe common variable immunodeficiency with autoimmunity due to homozygous stop codon mutations of LRBA

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-518919-19-00
Acronym
LRBA01
Enrollment
1
Registered
2024-11-04
Start date
2021-07-09
Completion date
2025-07-31
Last updated
2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and brain. LRBA deficiency (called LATAIE disease) may increase a person's risk of lymphoma, a type of cancer., autoimmunity, low levels of antibodies and recurrent infections. Excess of lymphocytes caused a variety of symptoms, LRBA deficiency due homozygous nonsense mutations. It is a rare genetic disorder of the immune system caused by mutation in LRBA gene. This disease results in excessive number of immune cells calls lymphocytes, lungs, the infiltration is most commun in the gut

Brief summary

In comparison with a pre treatment period of five years improvement of quality of life, weight, diarrhea episode and number of hospitalisations

Detailed description

Expression of LRBA by PBMC, normalisation of CTLA4 expression of CD4 T cells. Normalisation of soluble CD25 and follicular T helper cells

Interventions

DRUGTranslarna 1000 mg granules for oral suspension
DRUGTranslarna 250 mg granules for oral suspension

Sponsors

Centre Hospitalier Universitaire De Liege
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
In comparison with a pre treatment period of five years improvement of quality of life, weight, diarrhea episode and number of hospitalisations

Secondary

MeasureTime frame
Expression of LRBA by PBMC, normalisation of CTLA4 expression of CD4 T cells. Normalisation of soluble CD25 and follicular T helper cells

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026